RightRep EN · PT Open the app
BLOG

Can You Train on SSRIs? The Serotonin Swing Audit: The Medication Door the Mental-Health Wing Never Wrote — Where Both of the Gym's Default Scripts — the Pill Makes You Soft, Flat and Gain-Less, So Lower Your Expectations, and It's Just a Happy Pill, Train Like Nothing Changed — Fail the Reader (the Head-to-Head Column: SMILE's 156 Randomized Adults — 16 Weeks of Exercise Matched Sertraline on Every Depression Scale (P=.67), and at Ten Months the Exercise Group Relapsed Less While Every Own Workout Halved the Odds of the Diagnosis Coming Back (OR 0.49); the Add-It Column: TREAD's 126 Adults Not Remitted on Their SSRI — Exercise on Top of the Pill Remitted 28.3% at the Higher Dose vs 15.5% at the Lower (NNT 7.8); the Swing Column: Paroxetine Lab Humans Lifted ~4% More Fresh but Reached Task Failure Sooner and Perceived More Fatigue in Sustained Efforts — Heavy Singles Fine, High-Rep Grinders Negotiate; the Gains Null: No Human RCT Tests Whether SSRIs Tax Hypertrophy — the Forums Quote a Study That Doesn't Exist; the Stomach Column: SSRI+NSAID Multiplies Upper-GI Bleeding ×12.2 — the Ibuprofen-for-DOMS Habit Retires; the Salt-and-Rhythm Column: Antidepressant Hyponatremia OR 3.16 with SSRIs at 5.59% Event Rate, and QTc Risk Multiplies with the Sweat-Lost Electrolytes Heavy Training Depletes; the Bone Column: SSRI Users Lost Hip Density at −0.82% a Year vs −0.47% and Carry Fracture RR 1.72 — Resistance Training Is the Counter-Argument, Not the Risk; the Weight Column: ≥5% Weight-Gain Episodes 11.2 vs 8.1 per 100 Person-Years, Elevated for Six-Plus Years — the Program Is the Antidote; the Sweat Column: ~22% of Antidepressant Users Get Excessive Sweating — Dose-Dependent and Manageable; the Brazil Column: PNS 2019 — 10.9% of Adults 18–59 Meet MDD Criteria, Women 15.4% vs Men 6.0%; and the Competition Door: SSRIs Sit on No WADA List in Any Sport) — the Answer: Train — the Pill Is Training's Ally, Not Its Tax

By RightRep AI Assistant · · 24 min read

SSRIs are the door where the internet's two default scripts — the fear script: the pill makes you soft, flat and gain-less, so lower your expectations and your loading and the dismissive script: it's just a happy pill, train like nothing changed — both fail the reader at the exact question she walked in carrying, because this reader is one of three people: the newly prescribed one, three weeks into sertraline, whose gym suddenly feels flat and who wants to know whether the pill taxed the gains before they arrived; the years-on-escitalopram reader staring at a plateau, asking whether the molecule — not the programming — is the ceiling; or the Brazilian reader on the far side of a diagnosis file that now covers 10.9% of adults aged 18–59 (women 15.4%, men 6.0%) [16]. The fear script fails because the trial file runs the other way: in the randomized head-to-head, 16 weeks of aerobic training matched sertraline on both depression scales in 156 adults (P=.67) [1], and at ten months the exercise group had relapsed significantly less (p=.01) while exercising on her own during follow-up halved the odds of a depression diagnosis at the end (OR 0.49) [2] — and when the pill alone doesn't finish the job, adding the right exercise dose on top of it remitted 28.3% vs 15.5% of SSRI-nonremitted adults [3]. The dismissive script fails because the pill does edit real columns: fresh voluntary force rose ~4% under paroxetine in the lab while sustained efforts reached task failure sooner and felt heavier [7], the SSRI+NSAID combination multiplied upper-GI bleeding ×12.2 in the Danish cohort [9], antidepressant-associated hyponatremia carries an OR of 3.16 with a 5.59% SSRI event rate [10], and the bone file shows hip density declining −0.82% a year vs −0.47% in non-users [11]. So the fences come first. First: the never-self-edit fence — the molecule, the dose and any taper belong to the prescriber; an SSRI is never paused for a workout, a cut, or a "clearer head," because the discontinuation file is the one genuinely dangerous column at this door. Second: the stack fence — serotonergic combinations (tryptophan/5-HTP supplements, triptan antimigraine drugs, linezolid, MAO inhibitors, St John's wort) are the serotonin-syndrome door; any new supplement crosses the prescriber or pharmacist first [14]. Third: the stomach fence — the daily-ibuprofen-for-DOMS habit retires on this pill: ×3.6 alone becomes ×12.2 with an NSAID in the Danish file, so soreness management moves to load management, sleep and protein [9]. Fourth: the salt fence — long hot sessions get hydration with electrolytes and a food-salt plan, never plain-water flooding: hyponatremia risk [10] and the QTc file's hypokalemia multiplier [13] both live in the sweat-and-water arithmetic. With the fences standing, the file underneath is the friendliest inversion in the medication wing: train — the pill is training's ally, not its tax [1][3][4].

The short answer: train — the pill is the ally, not the tax

Strip the file to its spine. The head-to-head column: SMILE randomized 156 adults aged 50+ with major depressive disorder to 16 weeks of supervised aerobic exercise, sertraline, or the combination — and the groups did not differ on Hamilton or Beck scores at the end (P=.67); the drug only answered faster in the first weeks [1]. The relapse column: at ten months, remitted exercise-group subjects had relapsed significantly less than the medication group (p=.01), and own exercise during follow-up carried an OR 0.49 (p=.0009) against a depression diagnosis [2]. The add-it column: TREAD randomized 126 sedentary adults whose MDD had not remitted on an SSRI to two doses of exercise on top of the pill — adjusted 12-week remission 28.3% at 16 kcal/kg/week vs 15.5% at 4 (NNT 7.8), with the higher dose remitting 85.4% of men and 39.0% of women without a family history [3]. The effect-size columns: 41 trials in 2,264 participants put exercise's antidepressant effect at SMD −0.946 (95% CI −1.18 to −0.71), NNT 2 [4]; the overview of 97 systematic reviews (1,039 trials, 128,119 participants) prices physical activity at −0.43 for depression, −0.42 for anxiety, −0.60 for distress — with higher intensity buying more improvement [5]; and the publication-bias-adjusted meta-analysis lands at SMD 1.11 (0.79–1.43) with a fail-safe N of 1,057 [6]. The swing column: under paroxetine, brief unfatigued maximal contractions rose ~4% in torque while sustained contractions failed sooner, felt heavier, and lost 2–5% of voluntary activation under fatigue — the acute lab shape of this pill is fresh strength fine, long grinders negotiable [7]. The side-effect ledger: weight gain worth pricing (11.2 vs 8.1 episodes of ≥5% gain per 100 person-years, elevated six-plus years) [8], a stomach that hates NSAIDs [9], a salt-and-rhythm column [10][13], a bone column that argues for the barbell [11][12], and sweat — ~22% of antidepressant users [15]. That is the audit in one paragraph: the license is full, the pill and the program are on the same side of the table, and the fences are about ibuprofen, supplements, heat and salt — not about effort [1][3][9].

What the pill actually does: reuptake inhibition, in gym terms

The mechanics in a paragraph: SSRIs — sertraline, escitalopram, fluoxetine, paroxetine, citalopram — block the transporter that recycles serotonin out of the synapse, so the signal lingers; mood and anxiety columns move over weeks, and a set of peripheral files moves with them, because serotonin receptors sit in platelets (the bleeding column), in the brain's salt-and-water regulation (the hyponatremia column), in bone-forming cells (the bone column), in sweat regulation (the sweat column) and on the motoneurones themselves (the swing column) [7][9][10][11][15]. What the pill does not do is what the fear script claims: it is not a muscle-wasting agent, it does not block contraction, and it leaves the heart-rate response intact — unlike the medication wing's beta-blocker door (still in review in this library's pipeline), the pulse still answers effort normally on this molecule, and the prednisone corticosteroid door is a different drug family with its own file. The honest empty cell in the file matters as much as the filled ones: no randomized human trial has tested whether an SSRI taxes hypertrophy or strength gains from a training program — the forums speak confidently about cortisol and "gains killed" from a study that does not exist; what exists is one acute paroxetine lab file (fresh force slightly up, sustained efforts earlier to fail) [7], and a depression-treatment literature in which exercise performs at or near drug level [1][4][6]. Translation for the reader deciding whether to fear her prescription: the pill edits the fine print — bleeding, salts, sweat, bone, weight — and leaves the license, the pulse and (as far as any evidence has ever measured) the gains intact [1][3][7].

The head-to-head column: when the program was the drug

The steadiest receipt at this door is that the question "pill or training?" was once run as an actual randomized trial. SMILE — 156 adults aged 50 and over with diagnosed major depressive disorder, 16 weeks, three arms: a program of aerobic exercise, antidepressant medication with sertraline, or the combination [1]. The result that killed the old hierarchy: after 16 weeks the three groups were statistically indistinguishable on both the clinician-rated Hamilton scale and the self-report Beck inventory (P=.67), with all three improving significantly — the authors' own conclusion was that exercise "may be considered an alternative therapy" in this population [1]. The honest nuance: medication produced the faster initial response — the drug arm improved earlier in the growth curves, which matters for a reader in the acute weeks and is exactly why "trade the prescription for the gym" is not this post's advice [1]. The follow-up is the column's second receipt: reassessed at ten months, remitted subjects from the exercise arm had relapsed significantly less than the medication arm's (p=.01) — and across everyone, exercising on one's own during the follow-up window halved the odds of a depression diagnosis at its end (OR 0.49, p=.0009) [2]. Gym translation: the program is not a distraction from treatment — at the doses trials used, it performed as treatment, and its benefit was the kind that compounded after the supervised block ended [1][2].

The add-it column: the dose-response receipt for training on the pill

The most practically useful trial for the reader already on sertraline is TREAD, because it started where she stands: 126 sedentary adults aged 18–70 with major depressive disorder that had not remitted on SSRI treatment, randomized to augmentation with aerobic exercise at two doses — 4 kcal/kg/week (the public-health minimum) vs 16 kcal/kg/week (roughly the equivalent of a serious training habit) [3]. The remission file: adjusted remission at week 12 was 28.3% in the 16-kcal group vs 15.5% in the 4-kcal group, NNT 7.8 — and the moderators were stark: men on the higher dose remitted 85.4% vs 0.1% on the lower, women without a family history 39.0% vs 5.6% [3]. The intensity column repeats in the modern meta-file: the overview of 97 reviews found higher-intensity activity associated with greater symptom improvement [5], and the bias-adjusted meta-analysis found its largest effects at moderate-to-vigorous aerobic dosing [6]. Two honest caveats travel with TREAD: the between-group difference at the primary endpoint was a trend (P=.06), priced honestly here as NNT 7.8, and the trial tested augmentation, never replacement — every subject stayed on the SSRI [3]. Translation: the reader whose pill has done half the job does not ask the forums whether to accept the plateau — she adds a real, progressive, moderately-to-vigorously dosed program on top of the prescription and lets the two work the same side of the table [3][5].

The swing column: fresh force up, long grinders down

The barbell reader's narrowest question — "does the pill change the muscle itself?" — has exactly one human neurophysiology file, and it deserves its precise reading. Kavanagh and colleagues ran three studies of the acute effect of paroxetine (a strong reuptake inhibitor) on maximal and sustained voluntary contractions: brief unfatigued maximal elbow flexions rose ~4% in torque under the drug; but when contractions were sustained, time-to-task-failure fell and perceived fatigue rose, with twitch-interpolation showing voluntary activation of the fatigued muscle down 2–5% — the first in-vivo human evidence that serotonin at the motoneurone contributes to central fatigue [7]. This is the audit's namesake swing: fresh strength slightly up, endurance-shaped suffering slightly worse — heavy singles and short sets stand to be unaffected or a hair better; 20-rep grinders, long isometric holds and pacing-heavy endurance work may read heavier and arrive at failure sooner [7]. The honest framing is double: it is an acute lab file in healthy adults, not a training study on depressed patients taking their prescribed dose chronically — no trial has followed lifters through a hypertrophy block on their prescription [7]; and a perceived-effort shift of this size is handled by the same instrument every program already uses — honest tracking of load, reps and rep score, with rest timers long enough that the next set starts fresh [7]. If the long sets consistently feel heavier since the prescription started, that is a programming variable (rest, splits, session length) and a prescriber conversation about molecule and dose — never a reason to stop training [3][7].

The gains null and the motivation file: what honestly isn't in the literature

This library prices nulls the way other posts price effects, because at this door the null is the headline. The hypertrophy null: no randomized human trial has measured muscle growth or strength gains over a training program on vs off an SSRI — any forum claim of "proven gain-killing" is quoting folklore, not a citation; the closest evidence is the paroxetine swing (acute, bidirectional, small) [7] and the augmentation trials in which exercising SSRI users remitted at up to 85% [3]. The fitness-gains column is indirectly reassuring: exercise interventions in people taking antidepressants produced the depression outcomes above with no signal of blunted training response [3][4][5]. The motivation column runs the other way: the pill's therapeutic job — lifting the flatness that made the gym impossible — is the reader's best training asset; the depression wing's own doors carry the full file (training with anxiety or depression, exercise and depression, exercise and anxiety), and the effect sizes there are large enough — SMD 1.11 bias-adjusted [6], NNT 2 [4] — that the program and the prescription compound rather than compete [1][3][6]. The early-weeks honesty: SSRI onset is a weeks-scale process and the first fortnight can carry activation or flatness before the benefit lands — the same weeks SMILE's drug arm answered fastest in [1] — so the newly prescribed reader programs for attendance, not personal records, and lets the loading catch up as the head clears. The reader's translation: the gains tax is a myth with no receipt; the motivation tax was the depression, and both the pill and the bar are paying it down [1][3][6].

The stomach column: the one habit that retires on this pill

The sharpest practical fence at this door is not about training at all — it is about what the reader swallows for soreness. The Danish population cohort ran the arithmetic on its users' prescriptions: SSRI use alone ran upper-GI bleeding at 3.6 times the expected rate (95% CI 2.7–4.7) — an absolute rate difference of 3.1 episodes per 1,000 treatment-years — and concurrent NSAID use multiplied the relative risk to 12.2 (7.1–19.5), low-dose aspirin to 5.2 (3.2–8.0), with the risk returning to baseline after the SSRI stopped [9]. The gym translation is one sentence: the ibuprofen-for-DOMS habit retires on this pill — not because soreness management stops mattering, but because the painkillers-and-gains file already argued the anti-inflammatory crutch taxes adaptation, and on an SSRI it additionally rents a 12-fold bleeding risk [9]. What replaces it is the library's standard soreness kit: load management, sleep, protein, and the honest reading that DOMS is a signal, not an emergency. The fence has edges worth naming: an occasional NSAID for a genuine injury is a pharmacist or prescriber conversation — sometimes with stomach protection — not a forum thread [9]; and the reader on low-dose aspirin for a cardiac indication does not self-stop it either; she simply knows her file and tells her doctors she trains [9].

The salt-and-rhythm column: heat, water, potassium and the long session

Two side-effect files meet in the reader's water bottle, and this is the column where training habits genuinely interact with the pill. The salt file: antidepressant-associated hyponatremia runs at OR 3.16 (95% CI 1.91–5.23) across 39 studies and 8.17 million participants, with event rates by class — SSRIs 5.59%, SNRIs 7.44%, mirtazapine 1.02% [10]; the mechanism (SIADH-pattern water retention) turns dangerous in exactly the scenario endurance culture celebrates: hours of sweating replaced with plain water and nothing else. The rhythm file: QTc prolongation and Torsade-de-Pointes reports exist for citalopram, fluoxetine and paroxetine, but — the review's own framing — "as a rule" only when additional risk factors stack: age over 65, pre-existing cardiac disease, bradycardia, female sex, supratherapeutic levels, other QT-prolonging drugs, hypokalemia and hypomagnesemia [13] — and hypokalemia and hypomagnesemia are precisely what heavy sweat sessions leak. The combined translation is operational, not fearful: long hot sessions get electrolytes with the water, food salt across the day, and duration sense — the hydration file's discipline upgraded from "drink lots" to "replace what's in the sweat"; symptoms that stop a session (headache, confusion, nausea with bloating during long endurance work, new fainting or palpitations) are medical attention, not another set [10][13]; and the reader stacking any additional medication gets her potassium and an occasional ECG checked as part of normal care — the review's own recommendation for anyone on psychotropics with risk factors [13].

The bone column: the strongest keep-lifting receipt in the file

The side-effect column that argues loudest for the barbell is bone. The cohort receipt: among the older women of the Study of Osteoporotic Fractures cohort, total-hip density declined −0.82% per year in SSRI users vs −0.47% per year in non-users (P<.001), adjusted for depression — while tricyclic users matched the non-user rate [11]. The fracture receipt: across 13 cohort and case-control studies, SSRI use carried a fracture relative risk of 1.72 (95% CI 1.51–1.95), holding at 1.70 after bone-density adjustment and 1.74 after depression adjustment [12]. The honest wrinkle that keeps this column fair: in the two prospective women's cohorts, SSRI use was not significantly associated with measurable bone loss over time (P=0.29) — the fracture signal stands even where density-measured mediation is unclear, which is exactly why the file is priced as a long-horizon column rather than an alarm [12]. The training translation is the cleanest inversion at this door: resistance training is the documented, load-bearing stimulus for bone — the reader on a years-scale SSRI prescription has one more reason, not one fewer, to keep a progressive lifting habit for decades; and the companion doors for the same reader (lifting and bone, building muscle after 40) carry the program [11][12].

The weight and sweat columns: the body-shape files, priced honestly

Two cosmetic-adjacent columns get straight numbers because they drive more quiet quitting than any other side effect. The weight file: in the 10-year UK population cohort, episodes of ≥5% weight gain ran 11.2 per 100 person-years on antidepressants vs 8.1 off (adjusted rate ratio 1.21, 95% CI 1.19–1.22), and the risk stayed elevated for at least six years of follow-up [8]. That is a real, slow, average drag — roughly one extra gain episode per 33 person-years treated — and the response it earns here is the opposite of the fear script's: training is the antidote, not the casualty; the reader managing her weight on an SSRI needs the progressive overload habit and the honest kitchen file more, not less [8]. The sweat file: antidepressant-induced excessive sweating touches ~22% of users and quietly sinks medication adherence — it is dose-dependent, often timing-dependent, and manageable (dose adjustments, timing changes, and where needed glycopyrrolate-type management written by the prescriber) [15]. The reader drenching shirts mid-set does not choose between the pill and the gym; she files the sweat at the next prescription visit — the guideline exists precisely so primary care can act on it [15].

The Brazil column: the PNS file and the scale of the door

The pt-BR twin of this door exists on the scale of a national statistic: Brazil's own 2019 National Health Survey (Pesquisa Nacional de Saúde), 65,803 adults interviewed with the PHQ-9 in hand, found 10.9% of adults aged 18–59 meeting criteria for major depressive disorder — 15.4% of women against 6.0% of men — with prevalence climbing steeply in the multimorbidity file, the chronic-disease combinations the gym reader increasingly carries [16]. Two consequences follow. First, the door's size: at PNS scale, the medicated-or-diagnosed Brazilian reader is not a niche — she is one in nine adults, two in nine women, and the sertraline-in-the-gym-bag scenario is ordinary life at any academy in the country [16]. Second, the evidence bridge: the strongest bias-adjusted exercise-for-depression meta-analysis in the file is Brazilian-led — Schuch and colleagues from Porto Alegre — putting the program's effect at SMD 1.11 (0.79–1.43) with a fail-safe N of 1,057 [6]; the Brazilian reader is not importing a foreign intervention, she is importing her own literature's result [6][16]. The pt-BR program translation is identical to the EN one: the prescription is never self-edited, the ibuprofen habit retires, the hot-day water bottle carries salt, the barbell protects the bone column — and the program compounds with the pill against the diagnosis underneath [1][3][9][11][16].

The anti-doping door: if you compete

One column closes easier here than anywhere else in the medication wing: under the WADA Prohibited List, SSRIs are not prohibited — in any sport, in or out of competition [17]. There is no therapeutic-use exemption to file, no molecule on a monitoring program, no fence at the platform: where beta-blockers fence the precision sports and the anabolic file fences everything, the antidepressant file fences nothing [17]. The competitive reader's only note is the general one every supplement-taker carries: the prescription itself is clean, but anything stacked on top of it — pre-workout blends, "mood" supplements, 5-HTP — owns both the serotonin-syndrome question [14] and the contaminated-supplement question, which is why the stack fence routes through the prescriber and a tested-supplement policy rather than through the checkout button [14][17].

The program in gym terms: what stops, what ramps, what never changes

Stops and refers, today: any plan to pause, halve or taper the pill for a workout, a cut or a competition — that edit belongs to the prescriber, and the discontinuation file is why; serotonergic stacks (5-HTP, St John's wort, triptans added without review) — pharmacist or prescriber first [14]; symptoms that stop a session — confusion or nausea-bloating on a long hot effort [10], new fainting or palpitations [13], black or bloody stool on the NSAID habit [9] — medical attention, not another set.

Retires the habit, not the license: the daily ibuprofen-for-DOMS routine — ×12.2 on the bleeding file, replaced by load management, sleep and protein [9]; the plain-water-only bottle on long hot sessions — replaced by electrolytes-with-water and food salt [10][13]; the forum's gains-tax narrative — replaced by the actual file: fresh force intact, long grinders negotiable, hypertrophy untested and untaxed by any evidence [7].

Ramps exactly as the trials did: attendance first in the early prescription weeks — the drug arm answered fastest in SMILE's first fortnight, the program caught up by week 16 and passed on relapse at month ten [1][2]; then progressive, moderate-to-vigorous dosing — TREAD's 16 kcal/kg/week arm is the receipt for dose matters [3], the overview's intensity gradient for intensity matters [5], with zone 2 as the aerobic base and warm-up ladders as the daily door in.

Never changes: progressive overload — graded, patient, honest — honest tracking of load, reps and RPE (the rep score and form check exist so effort is measured, not guessed), set structure with rest long enough for the fresh-force file [7], tempo controlled, symmetry kept honest; the bone-column barbell for the years-scale reader [11][12]; the salt-and-water discipline in heat [10][13]; the prescriber-owned molecule and the sick-day rules; and the companion doors for the files that cross over — anxiety and depression, exercise and depression, stress, painkillers, sleep — with after-40 muscle for the reader building the habit for the bone column's long game.

The bottom line

  • The head-to-head column: SMILE, 156 randomized adults — 16 weeks of exercise matched sertraline on every depression scale (P=.67); the drug answered faster, the program caught up [1].
  • The relapse column: at ten months the exercise arm relapsed less (p=.01); own exercise halved the odds of the diagnosis (OR 0.49, p=.0009) [2].
  • The add-it column: TREAD, 126 SSRI-nonremitted adults — exercise on top of the pill remitted 28.3% at 16 vs 15.5% at 4 kcal/kg/week (NNT 7.8); high-dose men 85.4% [3].
  • The effect-size columns: SMD −0.946 (−1.18 to −0.71), NNT 2 across 41 trials [4]; overview of 97 reviews — depression −0.43, anxiety −0.42, distress −0.60, higher intensity better [5]; bias-adjusted SMD 1.11 (0.79–1.43) [6].
  • The swing column: acute paroxetine — fresh MVC torque ~+4%, sustained efforts to failure sooner with perceived fatigue up and voluntary activation down 2–5% [7].
  • The gains null: no human RCT tests SSRI-vs-hypertrophy — the gains-killing claim has no citation to lose [7].
  • The stomach column: SSRI ×3.6 upper-GI bleed alone, ×12.2 with an NSAID, ×5.2 with low-dose aspirin; absolute +3.1 per 1,000 treatment-years — retire the ibuprofen habit, keep the occasional-injury conversations with the pharmacist [9].
  • The salt-and-rhythm column: hyponatremia OR 3.16, SSRI event rate 5.59% [10]; QTc/TdP risk multiplies with hypokalemia and hypomagnesemia — sweat-lost electrolytes belong in the water bottle [13].
  • The bone column: hip density −0.82%/yr on SSRIs vs −0.47% off [11]; fracture RR 1.72 (1.51–1.95) [12] — the barbell is the counter-argument.
  • The weight and sweat columns: ≥5% gain episodes 11.2 vs 8.1 per 100 person-years, elevated 6+ years — train through it [8]; excessive sweating in ~22% of users, dose-dependent and manageable at the prescriber's desk [15].
  • The Brazil column: PNS 2019 — 10.9% of adults 18–59 meet MDD criteria, women 15.4% vs men 6.0% [16]; the strongest exercise-for-depression meta in the file is Brazilian-led [6].
  • The competition door: SSRIs sit on no WADA list, in or out of competition, any sport [17].
  • The honest nulls: the swing is an acute healthy-adult lab file, not chronic-prescription training data [7]; the TREAD dose difference was a trend at the primary endpoint (P=.06) priced as NNT 7.8 [3]; and the fracture file's density mediation is unresolved (P=0.29 in the prospective women's cohorts) [12].

Train like the file reads: the pill and the program are on the same side of the table — and the camera counts the reps of the long game at rightrep.app.

This post was written by the RightRep AI Assistant — the same AI that counts and scores your reps at rightrep.app.

Sources

  1. Blumenthal JA, Babyak MA, Moore KA, et al. Effects of exercise training on older patients with major depression. Archives of Internal Medicine, 1999;159(19):2349–2356. pubmed.ncbi.nlm.nih.gov
  2. Babyak M, Blumenthal JA, Herman S, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosomatic Medicine, 2000;62(5):633–638. pubmed.ncbi.nlm.nih.gov
  3. Trivedi MH, Greer TL, Church TS, et al. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. Journal of Clinical Psychiatry, 2011;72(5):677–684. pubmed.ncbi.nlm.nih.gov
  4. Heissel A, Heinen D, Brokmeier LL, et al. Exercise as medicine for depressive symptoms? A systematic review and meta-analysis with meta-regression. British Journal of Sports Medicine, 2023;57(16):1049–1057. pubmed.ncbi.nlm.nih.gov
  5. Singh B, Olds T, Curtis R, et al. Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews. British Journal of Sports Medicine, 2023;57(18):1203–1209. pubmed.ncbi.nlm.nih.gov
  6. Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: a meta-analysis adjusting for publication bias. Journal of Psychiatric Research, 2016;77:42–51. pubmed.ncbi.nlm.nih.gov
  7. Kavanagh JJ, McFarland AJ, Taylor JL. Enhanced availability of serotonin increases activation of unfatigued muscle but exacerbates central fatigue during prolonged sustained contractions. The Journal of Physiology, 2019;597(1):319–332. pubmed.ncbi.nlm.nih.gov
  8. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. BMJ, 2018;361:k1951. pubmed.ncbi.nlm.nih.gov
  9. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Archives of Internal Medicine, 2003;163(1):59–64. pubmed.ncbi.nlm.nih.gov
  10. Gheysens T, Van Den Eede F, De Picker L. The risk of antidepressant-induced hyponatremia: a meta-analysis of antidepressant classes and compounds. European Psychiatry, 2024;67(1):e20. pubmed.ncbi.nlm.nih.gov
  11. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Archives of Internal Medicine, 2007;167(12):1240–1245. pubmed.ncbi.nlm.nih.gov
  12. Wu Q, Bencaz AF, Hentz JG, Crowell MD. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporosis International, 2012;23(1):365–375. pubmed.ncbi.nlm.nih.gov
  13. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Deutsches Ärzteblatt International, 2011;108(41):687–693. pubmed.ncbi.nlm.nih.gov
  14. Boyer EW, Shannon M. The serotonin syndrome. New England Journal of Medicine, 2005;352(11):1112–1120. pubmed.ncbi.nlm.nih.gov
  15. Thompson S, Johnson D, Lindgren T, Compton L, Chen JL. Clinical practice guideline for primary care providers in the management of antidepressant-induced hyperhidrosis: a quality improvement project. Journal of the American Association of Nurse Practitioners, 2020;33(11):1080–1086. pubmed.ncbi.nlm.nih.gov
  16. Sousa NFDS, Barros MBA, Medina LPB, Malta DC, Szwarcwald CL. Association of major depressive disorder with chronic diseases and multimorbidity in Brazilian adults, stratified by gender: 2019 National Health Survey. Revista Brasileira de Epidemiologia, 2021;24(suppl 2):e210015. pubmed.ncbi.nlm.nih.gov
  17. World Anti-Doping Agency. The Prohibited List (current edition). wada-ama.org